SHANK3 HAPLOINSUFFICIENCY
Clinical trials for SHANK3 HAPLOINSUFFICIENCY explained in plain language.
Never miss a new study
Get alerted when new SHANK3 HAPLOINSUFFICIENCY trials appear
Sign up with your email to follow new studies for SHANK3 HAPLOINSUFFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy injection into the brain aims to treat rare genetic disorder
Disease control OngoingThis early-stage trial tests a single injection of RB001, a gene therapy, directly into the fluid around the brain of children with Phelan-McDermid syndrome caused by SHANK3 gene changes. The study includes up to 8 children aged 3 to 17 and primarily checks whether the treatment …
Matched conditions: SHANK3 HAPLOINSUFFICIENCY
Phase: PHASE1 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Gene therapy for rare genetic syndrome moves to Long-Term safety check
Disease control ENROLLING_BY_INVITATIONThis study follows children with Phelan-McDermid syndrome (a rare genetic disorder causing developmental delays) who received a single dose of RB001 gene therapy injected into the brain. Researchers will monitor them for up to 5 years to see if the treatment is safe and whether i…
Matched conditions: SHANK3 HAPLOINSUFFICIENCY
Phase: PHASE1 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC